Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response-Reference-Cited by-同舟云学术

Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response

Published:2018-05 Issue: Volume:179 Page:53-60
ISSN:1874-3919
Container-title:Journal of Proteomics
language:en
Short-container-title:Journal of Proteomics

Author:

Bowden D.L.^ORCID,Sutton P.A.,Wall M.A.,Jithesh P.V.,Jenkins R.E.,Palmer D.H.,Goldring C.E.,Parsons J.L.,Park B.K.,Kitteringham N.R.,Vimalachandran D.

Funder

Bowel Disease Research Foundation

Publisher

Elsevier BV

Subject

Biochemistry,Biophysics

Reference37 articles.

1. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision;Quirke;Lancet,1986

2. Training and quality assurance for rectal cancer: 20 years of data is enough;Quirke;Lancet Oncol.,2003

3. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence?;Heald;Br. J. Surg.,1982

4. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997;Heald;Arch. Surg.,1998

5. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit;Nagtegaal;Am. J. Surg. Pathol.,2002

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myoferlin: A Potential Marker of Response to Radiation Therapy and Survival in Locally Advanced Rectal Cancer;International Journal of Radiation Oncology*Biology*Physics;2024-06

2. Proteomic and metabolomic signatures of rectal tumor discriminate patients with different responses to preoperative radiotherapy;Frontiers in Oncology;2024-02-12

3. Targeting acid ceramidase enhances antitumor immune response in colorectal cancer;Journal of Advanced Research;2023-12

4. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients;Cancer Letters;2023-05

5. Personalized medicine;Metabolomics;2023